KalVista Pharmaceuticals, Inc. (FRA:4XC1)

KalVista Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is May - April.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 19, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Market Capitalization	679	603	448	264	296	505
Market Cap Growth	44.62%	34.74%	69.56%	-10.92%	-41.24%	183.52%
Enterprise Value	657	474	384	116	120	464
Last Close Price	13.30	11.70	10.00	7.65	11.96	20.60
PS Ratio	544.81	-	-	-	-	-
PB Ratio	19.05	7.18	2.32	1.81	1.69	2.36
P/TBV Ratio	19.05	7.18	2.32	1.81	1.69	2.36
EV/FCF Ratio	-4.47	-	-	-	-	-
Debt / Equity Ratio	3.40	1.18	0.04	0.05	0.04	0.02
Net Debt / Equity Ratio	-1.30	-1.14	-0.98	-0.88	-0.85	-0.94
Net Debt / EBITDA Ratio	0.26	0.58	1.45	1.28	1.65	4.24
Net Debt / FCF Ratio	0.32	0.71	2.28	1.85	2.00	8.03
Asset Turnover	0.01	-	-	-	-	-
Quick Ratio	5.16	5.22	9.70	11.18	15.81	26.67
Current Ratio	5.37	5.35	9.90	11.46	16.73	27.04
Return on Equity (ROE)	-190.18%	-121.50%	-68.90%	-53.69%	-37.23%	-27.13%
Return on Assets (ROA)	-60.98%	-48.34%	-41.94%	-35.80%	-25.38%	-19.86%
Return on Capital Employed (ROCE)	-114.50%	-91.40%	-66.10%	-65.90%	-50.20%	-22.10%
Earnings Yield	-26.14%	-26.80%	-26.45%	-31.88%	-26.35%	-7.62%
FCF Yield	-21.61%	-22.40%	-18.64%	-26.23%	-25.31%	-4.98%
Buyback Yield / Dilution	-29.51%	-34.98%	-31.89%	-13.96%	-28.17%	-7.58%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.